Patents by Inventor Erhao ZHANG

Erhao ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240130071
    Abstract: An outdoor electric cabinet and an air duct structure thereof are provided. The air duct structure is used to guide airflow to an air inlet side of a fan. The air duct structure includes an air inlet port, a flow-guiding cavity and an air distribution assembly. The air inlet port is configured to introduce external airflow into the air duct structure. The flow-guiding cavity is formed between the air inlet port and the air inlet side of the fan. The air distribution assembly is arranged in the flow-guiding cavity to uniformly distribute an air suction force of the air inlet port. The airflow suction force at the air inlet port is distributed more uniformly by the air distribution assembly, which effectively weakens the maximum wind speed on the shortest path.
    Type: Application
    Filed: July 19, 2023
    Publication date: April 18, 2024
    Applicant: Sungrow Hydrogen Sci. & Tech. Co., Ltd.
    Inventors: Xiangwen Ge, Yuqin Jiang, Shengwei Gong, Zhitong Zhang, Erhao Chen
  • Patent number: 11932872
    Abstract: The present invention discloses a novel switchable dual chimeric antigen receptor-T (sdCAR-T) cell and a construction method and use thereof, which fall within the field of cellular immunotherapy for tumors. The dual chimeric antigen receptor consists of a first chimeric antigen receptor for MSLN and a second chimeric antigen receptor for FITC. A dual-targeted functional T cells regulated by specific exogenous bifunctional molecules is constructed, and the exogenous molecules are used to preliminarily discuss the in vivo and in vitro activity of the dual chimeric antigen receptor-T cell. By means of in vitro and in vivo tests, it is confirmed that the activation mode of the constructed CAR-T cell is controlled by the combination of endogenous tumor antigens and exogenous bifunctional molecules, and this combined regulation mode can significantly improve the safe application of CAR-T cell immunotherapy.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: March 19, 2024
    Assignee: NANJING ANJI BIOLOGICAL TECHNOLOGY CO., LTD
    Inventors: Hanmei Xu, Erhao Zhang
  • Publication number: 20200224162
    Abstract: The present invention discloses a novel switchable dual chimeric antigen receptor-T (sdCAR-T) cell and a construction method and use thereof, which fall within the field of cellular immunotherapy for tumors. The dual chimeric antigen receptor consists of a first chimeric antigen receptor for MSLN and a second chimeric antigen receptor for FITC. A dual-targeted functional T cells regulated by specific exogenous bifunctional molecules is constructed, and the exogenous molecules are used to preliminarily discuss the in vivo and in vitro activity of the dual chimeric antigen receptor-T cell. By means of in vitro and in vivo tests, it is confirmed that the activation mode of the constructed CAR-T cell is controlled by the combination of endogenous tumor antigens and exogenous bifunctional molecules, and this combined regulation mode can significantly improve the safe application of CAR-T cell immunotherapy.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 16, 2020
    Inventors: Hanmei XU, Erhao ZHANG